A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology

Comptes Rendus Mathematique

Volumn 350, Issue 1-2, 2012, Pages 23-28

  Benzekry, Sébastien ^a   Chapuisat, Guillemette ^a   Ciccolini, Joseph ^b   Erlinger, Alice ^a   Hubert, Florence ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b University of the Mediterranean Aix Marseille II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856424718     PISSN: 1631073X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crma.2011.11.019     Document Type: Article

References (14)

1. Barbolosi D., Benabdallah A., Hubert F., Verga F. Mathematical and numerical analysis for a model of growing metastatic tumors. Math. Biosci. 2009, 218:1-14.
2. Barbolosi D., Freyer G., Ciccolini J., Iliadis A. Optimisation de la posologie et des modalités d'administration des agents cytotoxiques à l'aide d'un modèle mathématique. Bull. Cancer 2003, 90:167-175.
3. Barbolosi D., Verga F., Benabdallah A., Hubert F., Mercier C., Ciccolini J., Faivre C. Modélisation du rique d'évolution métastatique chez les patients supposés avoir une maladie localisée. Oncologie 2011, 13:528-533.
4. Benzekry S. Mathematical and numerical analysis of a model for antiangiogenic therapy in metastatic cancers. M2AN 2012, 46:207-237.
5. S. Benzekry, N. André, A. Benabdallah, J. Ciccolini, C. Faivre, F. Hubert, D. Barbolosi, Modelling the impact of anticancer agents on metastatic spreading, MMNP (2011), in press.
6. Bruno R., Vivier N., Vergniol J.C., De Phillips S.L., Montay G., Sheiner L.B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm. 1996, 24:153-172.
7. Davies J.M., Goldberg R.M. Treatment of metastatic colorectal cancer. Semin. Oncol. 2011, 38:552-560.
8. de Jong R.S., Mulder N.H., Uges D.R.A., Kaul S., Winograd B., Sleijfer D.T., Groen H.J.M., Willemse O.H.B. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br. J. Cancer 1997, 75:1660-1666.
9. Folkman J. Tumor angiogenesis: therapeutic implications. New England J. Med. 1971, 285:1182-1186.
10. Gompertz B. On the nature of the function expressive of the law of human mortality and on a new mode of determining the value of life contingencies. Phil. Trans. Roy. Soc. London 1825, 115:513-583.
11. Hahnfeldt P., Panigraphy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999, 75:4770-4775.
12. Iwata K., Kawasaki K., Shigesad N. A dynamical model for the growth and size distribution of multiple metastatic tumors. J. Theor. Biol. 2000, 203:177-186.
13. Jain R.K. Molecular regulation of vessel maturation. Nature Med. 2003, 9:685-693.
14. Sargent D., Grothey A. Sound footing or slippery slope? The value of secondary analyses of randomized trials. J. Clin. Oncol. 2007, 25:3191-3193.